ANIK (55) OSUR (36) TMCI (40) CLPT (19) ⌘ Pro Terminal →

InfuSystems Holdings Inc. (INFU) — RQD Stock Rating Cockpit

$14.45 +0.91% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $14.51

InfuSystems Holdings Inc. (INFU) earns a Roarable Rating of B+ (Buy) with 78/100 RQD Confidence. High-quality cash engine (56% profit margin, 13% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 78/100 (B+) historically ranked in the Top 10% of excess returns over the next 90 days (+7.9% avg 90D alpha vs SPY • 70.6% hit rate) →

ROARABLE B+ • BUY Cap $287.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on INFU Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is INFU stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, InfuSystems Holdings Inc. (NYSE: INFU) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 78/100 at a spot price of $14.45 (+0.91% 1D, market cap $287.8M). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, INFU ranks #22 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does INFU compare to ANIK and OSUR in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), INFU carries a Roarable B+ (78/100 RQD), trailing P/E of 43.4x, gross margin of 56.0%, and ROIC of 12.8%. By comparison, ANIK (Anika Therapeutics Inc.) holds a D+ grade (55/100 RQD, P/E N/A, ROIC -10.2%, cap $291.6M) and OSUR (OraSure Technologies Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $281.4M). Among the 5-stock peer group, INFU leads on earnings multiple (43.4x) while INFU leads on capital efficiency (12.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for INFU?

▼

Per INFU's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001337013), InfuSystems Holdings Inc. generated $143.4M in revenue (+6.4% YoY), $6.6M in net income, and $23.8M in free cash flow against $100.6M in total assets and $19.6M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Priced at 43x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $14.51 (+0.40%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 16.6% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 78/100 (B+) historically ranked in the Top 10% of excess returns over the next 90 days (+7.9% avg 90D alpha vs SPY • 70.6% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B+

3-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk A-

Each axis scored 0–20

12M PRICE TARGET CONE+9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for INFU)Realized 20D OHLCV Swing Band: ±7.3%

Deterministic 5-Pillar Attribution (78/100 Composite)

🔍 WHY INFU SCORES 78/100 (B+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (23% of score)

Altman Z-Score 5.16 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9

▲ #2 Bullish Driver: Macro Regime Fit+16/20 pts (21% of score)

FRED Regime × Technicals: 97% of 52W Range • RSI-14 at 63.5 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Cash Engine Quality14/20 pts (-6 pt drag)

Capital intensity & 8.3% operating margin leave 6 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B$13.60+1% Next Q

Q2 (-2Q)

Grade B$13.74+0.5% Next Q

Q3 (-1Q)

Grade B+$13.81+4.6% Next Q

Current

Grade B+$14.45+7.9% Hist 90D α

Trajectory: B (70) → B+ (78)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the INFU Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 78/100 (B+) score, INFU faces multiple-compression risk if 43.4x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Priced at 43x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 53.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($13.02) or 200D SMA ($10.36) invalidates the momentum regime and cuts Target Base ($15.75) toward Bear Floor ($11.85).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $INFU• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “INFU Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 78%NO 22%Trade / Inspect Odds →

RSI-14 MOMENTUMBULLISH MOMENTUM

63.530 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

5.16>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

9 / 99-Pt Accounting

52-WEEK LASER RANGE97% OF RANGE

L: $7$14.45H: $15

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (56% profit margin), though cash flow growth is moderate rather than explosive right now.

Factor Grade: B-RQD 14 / 20

2. Big Money & Insiders● BUYING

Are whales & executives buying or selling?

Hedge funds and options traders are leaning bullish, showing strong institutional appetite.

Factor Grade: BRQD 30 / 40

3. Hidden Risks & Market Weather● ALL CLEAR

SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: A-RQD 34 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bullish on INFU

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BULLISH (70)

12.8% ROIC with 56.0% gross margin and 8.29% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BULLISH (90)

Altman-Z 5.16 and Piotroski 9/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BULLISH (77)

30/40 institutional & smart-money positioning score with 16/20 macro alignment.

Bull Case: Why Buyers Like INFU

✓Big institutional funds and options desks are actively positioning on the bullish side.
✓Company leadership has skin in the game with net positive insider conviction.
✓Clean SEC annual filing review with no major hidden accounting time-bombs.

Bear Case: What Could Go Wrong

!Priced at 43x earnings—high expectations leave less room for a lukewarm quarter.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (INFU Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

INFU // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +39.08%⚡ TESTING RESISTANCE

2026-11-02O $14.32H $14.45L $14.32C $14.45VOL 74.9K

RES: $14.70SUP: $9.74SMA50: $13.02SMA200: $10.36

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

INFU Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 INFU Butterfly Map → + Track INFU →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

32.6%/yr Implied 5Y Growth

vs. +6.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on INFU today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for INFU. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for INFU today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INFU)

Health Care Rank #22 of 1016 ⚔️ ANIK vs INFU Full Matrix →

1. Head-to-Head Health Care Peer Comparison (INFU vs. ANIK, OSUR, TMCI, CLPT)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, InfuSystems Holdings Inc. (INFU) ranks #22 by composite RQD confidence (78/100, grade B+) and #525 by equity capitalization ($287.8M). Within this direct 5-issuer industry benchmark cohort, INFU leads on earnings valuation at 43.4x trailing P/E, while INFU leads on capital efficiency and profitability with 12.8% ROIC and 56.0% gross margin. INFU currently leads its immediate peer cohort in composite quantitative strength at 78/100 (B+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
INFU ACTIVE InfuSystems Holdings Inc.	B+	78/100	43.4x	56.0%	12.8%	+0.91%	$287.8M	Benchmark Subject
ANIK Anika Therapeutics Inc.	D+	55/100	—	56.6%	-10.2%	+1.11%	$291.6M	/anik-vs-infu →
OSUR OraSure Technologies Inc.	D-	36/100	—	41.9%	-35.0%	-0.49%	$281.4M	/osur-vs-infu →
TMCI Treace Medical Concepts Inc.	D-	40/100	—	79.8%	-32.4%	+4.76%	$329.1M	/tmci-vs-infu →
CLPT ClearPoint Neuro Inc.	E	19/100	—	61.4%	-35.0%	+1.23%	$342.7M	/clpt-vs-infu →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001337013

In its most recent audited fiscal period (FY2025, filed 2025-12-31), InfuSystems Holdings Inc. (INFU) reported GAAP revenue of $143.4M (+6.4% vs. FY2024 revenue of $134.9M , and +14.0% cumulative change since FY2023) , GAAP net income of $6.6M, operating cash flow of $24.4M, and free cash flow of $23.8M (+23.1% YoY). On the balance sheet, INFU closed FY2025 with $100.6M in total assets against $19.6M in total debt (Altman Z-Score: 5.16, Piotroski F-Score: 9/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$143.4M	$6.6M	$24.4M	$23.8M	$100.6M	$19.6M
FY2024 (FY)	2024-12-31	$134.9M	$2.3M	$20.5M	$19.4M	$103.6M	$23.9M
FY2023 (FY)	2023-12-31	$125.8M	$872.0K	$11.2M	$11.2M	—	—

3. INFU Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is INFU stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does INFU compare to ANIK and OSUR in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for INFU?

Where is INFU trading relative to its 50-day, 200-day, and 52-week technical levels?

INFU last traded at $14.45 (+0.91% on volume of 74,910 shares), positioning the stock +10.98% above its 50-day simple moving average ($13.02) and +39.48% above its 200-day simple moving average ($10.36). Across its 52-week range of $7.29 to $14.64, INFU sits at the 97.4% percentile with a 14-day RSI of 63.5 (BULLISH MOMENTUM) and an implied next-earnings move of ±7.3% ($13.40 to $15.50).

INFU Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell INFU stock right now?

InfuSystems Holdings Inc. (INFU) currently earns a Roarable Rating of B+ (Buy — BUY) with 78/100 RQD Confidence. High-quality cash engine (56% profit margin, 13% return on capital) with steady institutional support.

What is INFU's 12-month price target and RQD AI Jury consensus?

INFU's 12-month base price target is $15.75 (range $11.85 to $18.58), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: INFU RQD Cockpit INFU 12M Forecast INFU Earnings & Move INFU Dividends & DRIP INFU Insiders & 13F INFU Whale Options INFU Profit Sankey INFU News & Why